MLICM
HRTX icon

Metropolitan Life Insurance Company (MetLife)’s Heron Therapeutics HRTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,964
Closed -$11K – 974
2024
Q1 		$11K Sell
3,964
-2,197
-36% -$5.52K ﹤0.01% 2101
2023
Q4 		$10.5K Hold
6,161
– – ﹤0.01% 2165
2023
Q3 		$6.35K Buy
6,161
+468
+8% +$666 ﹤0.01% 2374
2023
Q2 		$6.6K Buy
5,693
+2,667
+88% +$4.76K ﹤0.01% 2441
2023
Q1 		$4.57K Sell
3,026
-3,100
-51% -$7.76K ﹤0.01% 2276
2022
Q4 		$15.3K Hold
6,126
– – ﹤0.01% 2125
2022
Q3 		$25.9K Hold
6,126
– – ﹤0.01% 1886
2022
Q2 		$17.1K Hold
6,126
– – ﹤0.01% 2118
2022
Q1 		$35K Sell
6,126
-20,791
-77% -$152K ﹤0.01% 1795
2021
Q4 		$246K Hold
26,917
– – ﹤0.01% 1878
2021
Q3 		$288K Hold
26,917
– – ﹤0.01% 1807
2021
Q2 		$418K Buy
26,917
+1,139
+4% +$18.1K 0.01% 1629
2021
Q1 		$418K Sell
25,778
-1,094
-4% -$19.5K 0.01% 1526
2020
Q4 		$569K Hold
26,872
– – 0.01% 1276
2020
Q3 		$398K Hold
26,872
– – 0.01% 1368
2020
Q2 		$395K Hold
26,872
– – 0.01% 1379
2020
Q1 		$315K Buy
26,872
+742
+3% +$13.9K 0.01% 1333
2019
Q4 		$614K Buy
26,130
+1,647
+7% +$36.4K 0.01% 1198
2019
Q3 		$453K Buy
24,483
+1,794
+8% +$33K 0.01% 1361
2019
Q2 		$422K Buy
22,689
+434
+2% +$8.67K 0.01% 1417
2019
Q1 		$544K Sell
22,255
-588
-3% -$15.4K 0.01% 1241
2018
Q4 		$593K Buy
22,843
+628
+3% +$17.3K 0.01% 1091
2018
Q3 		$703K Buy
22,215
+1,476
+7% +$55K 0.01% 1135
2018
Q2 		$806K Buy
20,739
+3,177
+18% +$101K 0.01% 1031
2018
Q1 		$485K Buy
17,562
+2,257
+15% +$51.2K 0.01% 1296
2017
Q4 		$277K Sell
15,305
-16,296
-52% -$266K ﹤0.01% 1682
2017
Q3 		$510K Hold
31,601
– – ﹤0.01% 1678
2017
Q2 		$438K Buy
31,601
+3,354
+12% +$48.6K ﹤0.01% 1795
2017
Q1 		$424K Buy
28,247
+2,233
+9% +$30.9K ﹤0.01% 1761
2016
Q4 		$341K Hold
26,014
– – ﹤0.01% 2003
2016
Q3 		$448K Hold
26,014
– – ﹤0.01% 1775
2016
Q2 		$470K Buy
26,014
+5,268
+25% +$103K ﹤0.01% 1739
2016
Q1 		$394K Hold
20,746
– – ﹤0.01% 1737
2015
Q4 		$554K Hold
20,746
– – ﹤0.01% 1561
2015
Q3 		$506K Buy
20,746
+3,630
+21% +$121K ﹤0.01% 1625
2015
Q2 		$533K Buy
+17,116
New +$322K ﹤0.01% 1701
2015
Q1 		– Sell
-22,917
Closed -$231K – 2303
2014
Q4 		$231K Hold
22,917
– – ﹤0.01% 2306
2014
Q3 		$191K Hold
22,917
– – ﹤0.01% 2399
2014
Q2 		$282K Buy
+22,917
New +$274K ﹤0.01% 2257

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s HRTX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 3,964 shares — an estimated $11K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in HRTX in Q2 2014 and held it in 39 quarters. The position peaked at $806K in Q2 2018. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,964 Heron Therapeutics shares in Q2 2024, an estimated $11K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Heron Therapeutics in Q2 2014 and held it in 39 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Heron Therapeutics position peaked at $806K in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.